Weijian Zhao

Weijian Zhao

Auto-generated profile, based on publicly available information

Weijian Zhao

Ph.D. Student, Research Center for Intelligent Robotics, School of Astronautics, Northwestern Polytechnical Univ., Xi’an, Shaanxi 710072, China. ORCID:

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
YZYixiang Zhan
Yixiang Zhan
WZWeipeng Zhao
Weipeng Zhao
KNKemin Ni
Kemin Ni
ZLZhaoce Liu
Zhaoce Liu
YSYanjun Su
Yanjun Su
CZChun-Ze Zhang
Chun-Ze Zhang
Immunotherapy has revolutionized cancer treatment and become one of the five pillars of cancer therapy. The clinical applications of immunotherapy have been adapted to range from the management of melanoma to most tumor types. As the clinical applications of cancer immunotherapies expand, understanding the treatment-related adverse events of these drugs becomes critical in clinical practice. We report a rare case of ocular immune-related side effects associated with camrelizumab that resulted in vision loss. A 56-year-old male patient was diagnosed with small cell lung cancer. The tumor involved the porta pulmonis and mediastinum upon initial diagnosis; therefore, surgery was not possible. Upon receiving the 10th immunotherapy session with camrelizumab 200 mg, the patient’s visual acuity began to decrease in his right eye and a central retinal vein occlusion. Optical coherence tomography revealed significant cystoid exudation in the macular area and vitreous hemorrhage. The patient underwent vitrectomy, phacoemulsification and intraocular lens implantation after symptom onset. Following surgery, the patient’s vision was limitedly restored. This is the first clinical report in China of central retinal vein occlusion and vitreous hemorrhage associated with anti-PD-1 therapy, ultimately leading to blindness. Although rare, clinical practitioners should be concerned about ocular adverse events associated with anti-PD-1 immunotherapy and develop a high index of suspicion for this possibility since ophthalmic manifestations that are rapidly detected, closely monitored, and appropriately managed are treatable.

1 January 2025 in Journal of Aerospace Engineering
Verified
Journal Article
Closed access
WZWeijian Zhao
Weijian Zhao
FZFan Zhang
Fan Zhang
PHPanfeng Huang
Panfeng Huang
HWHao Wen
Hao Wen
TCTi Chen
Ti Chen